Comparison of the efficacy between vonoprazan fumarate and rabeprazole combined with mucosal protectors for artificial ulcers after endoscopic submucosal dissection: a prospective randomized controlled study
10.3760/cma.j.cn321463-20231025-00434
- VernacularTitle:富马酸伏诺拉生与雷贝拉唑联合黏膜保护剂对内镜黏膜下剥离术后人工溃疡疗效的随机对照研究
- Author:
Xin GAO
1
;
Xuan LI
;
Yun WANG
;
Haisheng QIAN
;
Guoxin ZHANG
Author Information
1. 江苏省人民医院（南京医科大学第一附属医院、江苏省妇幼保健院）消化内科，南京 210029
- Keywords:
Proton pump inhibitors;
Vonoprazan fumarate;
Endoscopic submucosal dissection;
Artificial ulcer;
Efficacy
- From:
Chinese Journal of Digestive Endoscopy
2024;41(5):366-371
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the efficacy between vonoprazan fumarate and rabeprazole for the treatment of artificial ulcers after endoscopic submucosal dissection (ESD).Methods:In this prospective randomized controlled study, patients who underwent ESD between December 2021 and August 2023 at Jiangsu Province Hospital were enrolled and randomly divided into two groups. Vonoprazan fumarate combined with rebamipide (vonoprazan group) or rabeprazole combined with rebamipide (rabeprazole group) were given respectively from the 4th day after ESD. After 8 weeks, the healing of the ulcers was compared.Results:Ninety-one patients were enrolled in the study, including 51 in the vonoprazan group and 40 in the rabeprazole group. The ulcer area reduction rate of the vonoprazan group was significantly higher than that of the rabeprazole group (92.86%±3.80% VS 90.04%±4.28%, t=3.281, P=0.001), but there was no significant difference in the healing rate [15.69% (8/51) VS 7.50% (3/40), χ2=1.414, P=0.234] or the adverse event occurrence ( P>0.05) between the two groups. Conclusion:Vonoprazan fumarate can achieve better ulcer treatment without increasing the risk of adverse events.
